In early Phase I studies, ITu JX-594, a genetically engineered TK-mutant/GM-CSF expressing VAC, demonstrated highly promising results in patients with melanoma [78] and hepatocellular carcinoma (HCC) [79]. The gene discussed is CSF2; the disease is melanoma.